GLAXF 6-K
GSK plc (GSK)
6-K
2026-07-15
For: 2026-07-15
View Original
Added on
July 15, 2026
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of July 2026
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 15 July 2026, London UK
GSK completes acquisition of Nuvalent, Inc.
GSK plc (LSE/NYSE: GSK) today announced completion of
its acquisition
of Nuvalent, Inc.[1],
a Boston-based clinical-stage biopharmaceutical company focused on
creating precisely targeted oncology therapies.
The acquisition adds three lung cancer assets to GSK's oncology
portfolio. Zidesamtinib (NVL-520) and neladalkib (NVL-655)
are considered
potential best-in-class assets, based on clinical data, and
are under
FDA review for ROS1-positive and ALK-altered non-small cell lung
cancer (NSCLC) with target decision dates later this year. Both
have received FDA Breakthrough Therapy and Orphan Drug
Designations. If approved, they are expected to launch in 2026 with
multi-blockbuster potential. The acquisition also includes NVL-330
in phase I development for HER2-altered NSCLC.
Luke Miels, Chief Executive Officer, GSK, said: "Today's
deal completion accelerates our entry into lung cancer with
zidesamtinib and neladalkib and a platform for rapid expansion with
Ris-Rez, our B7-H3 targeted ADC in phase III development. There is
a clear need for these medicines in defined patient populations,
consistent with our approach of acquiring validated assets that aim
to improve standard of care."
Financial considerations
Under the terms of the agreement, GSK
completed a tender offer to acquire all of Nuvalent's outstanding
shares. The aggregate equity value of the transaction is
approximately $10.6 billion (£8.0 billion). Net of cash
acquired, GSK's aggregate investment is approximately $9.4 billion
(£7.1 billion).
About NSCLC
NSCLC is the most common form of lung cancer and is often
characterised by specific genetic alterations, such as those in
ALK, ROS1, or HER2. It can often metastasise (i.e. spread) to the
central nervous system. It primarily affects working-age
individuals. Current treatments are associated with mutation
resistance and side effects, including metabolic and neurologic
events, that can adversely impact patients' quality of
life.
About Nuvalent
Nuvalent (NASDAQ: NUVL) is a clinical-stage biopharmaceutical
company focused on creating precisely targeted therapies for
patients with cancer, designed to overcome the limitations of
existing therapies for clinically proven kinase targets. Leveraging
deep expertise in chemistry and structure-based drug design,
Nuvalent develops innovative small molecules that have the
potential to overcome resistance, minimize adverse events, address
brain metastases, and drive more durable responses. Nuvalent is
advancing a robust pipeline with investigational candidates for
ROS1-positive, ALK-positive, and HER2-altered non-small cell lung
cancer, and multiple discovery stage research
programs.
GSK in oncology
Our ambition in oncology is to help increase overall quality of
life, maximise survival and change the course of disease, expanding
from our current focus on blood and women's cancers into lung and
gastrointestinal cancers, as well as other solid tumours. This
includes accelerating priority programmes such as antibody-drug
conjugates Ris-Rez targeting B7-H3 and Mo-Rez targeting B7-H4, and
velzatinib, a highly selective KIT tyrosine kinase
inhibitor.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at www.gsk.com.
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Sarah
Clements
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
Alison
Hunt
|
+1 540 742 3391
|
(Washington
DC)
|
|
|
|
|
|
|
Investor
Relations:
|
Constantin
Fest
|
+44 (0)
7831 826525
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Steph
Mountifield
|
+44 (0)
7796 707505
|
(London)
|
|
|
Sam
Piper
|
+44 (0)
7824 525779
|
(London)
|
|
|
Joanna
Tuplin
|
+44 (0)
7788 351650
|
(London)
|
|
|
Dan
Smith
|
+44 (0)
7823 523885
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
Frannie
DeFranco
|
+1 215
751 3126
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the "Risk
Factors" section in GSK's Annual Report on Form 20-F for 2025, and
GSK's Q1 Results for 2026.
Registered in England & Wales:
No.
3888792
Registered Office:
79
New Oxford Street
London
WC1A
1DG
[1] GSK
press release issued 9 June. GSK enters agreement to acquire
Nuvalent, Inc. Available at:
https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-nuvalent-inc/.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: July
15, 2026
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|